Notable Upgrades: (AMZN), VMware (VMW), Valeant Pharma (VRX), Las Vegas Sands (LVS), Inc. (AMZN) was reiterated a ‘Buy’ by Axiom Capital analysts on Tuesday. The broker also raised its price target on the stock to $727 from $650, noting the e-commerce giant could very well embark on another aggressive spending cycle that could again test investor’s patience.

AMZN is currently printing a normal trading volume with the issue trading 1.99 million shares, compared to the average daily volume of 4.26 million. The stock began trading this morning at $608.60 to currently trade 0.66% higher from the prior days close of $608.61. On an intraday basis it has gotten as low as $605.53 and as high as $614.45. Inc. shares are priced at 877.65x this year’s forecasted earnings, compared to the industry’s 17.98x earnings multiple. The company’s current year and next year EPS growth estimates stand at 455.80% and 190.30%, compared to the industry growth rates of 10.00% and 19.50%, respectively. AMZN has a t-12 price-to-sales ratio of 2.84. EPS for the same period registers at $0.70. Inc. is up 112.01% year-over-year, compared with a 5.58% gain in the S&P 500.

Analysts at Drexel Hamilton upgraded their rating on the shares of VMware, Inc. (VMW). In a research note published on Tuesday, the firm lifted the name with a ‘Buy’ from ‘Hold’ rating as they like the valuation here.

VMware Inc. shares are currently priced at 26.85x this year’s forecasted earnings, compared to the industry’s 10.30x earnings multiple. Ticker has a PEG and forward P/E ratio of 1.01 and 14.15, respectively. Price/Sales for the same period is 3.89 while EPS is $2.21. Currently there are 10 analysts that rate VMW a ‘Buy’, 24 rate it a ‘Hold’. One analyst rates it a ‘Sell’.

VMW has a median Wall Street price target of $75 with a high target of $119.

Valeant Pharmaceuticals (VRX) was raised to ‘Buy’ from ‘Neutral’ with $155 target at Mizuho on Tuesday. Firm believes VRX could be subject to more negative media coverage as they await the results of its internal audit ; they think the name could be more resilient going forward even if the Street lowers estimates.

In a report published Tuesday, Gabelli & Co analysts initiated coverage on Las Vegas Sands Corp. (LVS) with a ‘Buy’ rating and $60 price target.

On valuation measures, Las Vegas Sands Corp. shares currently have a PEG and forward P/E ratio of 3.34 and 18.34, respectively. Price/sales for the same period is 3.18 while EPS is $2.78. Currently there are 9 analysts that rate LVS a ‘Buy’, 9 rate it a ‘Hold’. No analyst rates it a ‘Sell’.

LVS has a median Wall Street price target of $53 with a high target of $63.

In the past 52 weeks, shares of Las Vegas, Nevada-based company have traded between a low of $36.53 and a high of $65.35 and are now at $47.27.

Shares are down 18.43% year-over-year and 12.79% year-to-date.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.